PT3027642T - Construtos do fator 15 de diferenciação de crescimento (gdf-15) - Google Patents
Construtos do fator 15 de diferenciação de crescimento (gdf-15)Info
- Publication number
- PT3027642T PT3027642T PT147527113T PT14752711T PT3027642T PT 3027642 T PT3027642 T PT 3027642T PT 147527113 T PT147527113 T PT 147527113T PT 14752711 T PT14752711 T PT 14752711T PT 3027642 T PT3027642 T PT 3027642T
- Authority
- PT
- Portugal
- Prior art keywords
- gdf
- constructs
- differentiation factor
- growth differentiation
- growth
- Prior art date
Links
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 title 2
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 title 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361860723P | 2013-07-31 | 2013-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3027642T true PT3027642T (pt) | 2020-10-30 |
Family
ID=51358091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT147527113T PT3027642T (pt) | 2013-07-31 | 2014-07-31 | Construtos do fator 15 de diferenciação de crescimento (gdf-15) |
Country Status (35)
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2694092B1 (en) | 2011-04-08 | 2017-01-04 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| EP3683228A3 (en) * | 2012-01-26 | 2020-07-29 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) polypeptides |
| CA2862516C (en) | 2012-03-27 | 2023-02-14 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| KR101993714B1 (ko) | 2013-01-30 | 2019-06-28 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사 장애를 치료하는데 이용하기 위한 조성물과 방법 |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| US9862752B2 (en) | 2013-07-31 | 2018-01-09 | Amgen Inc. | Growth differentiation factor 15 (GDF-15) constructs |
| JP2015182969A (ja) * | 2014-03-21 | 2015-10-22 | 四国化成工業株式会社 | トリアゾールシラン化合物、該化合物の合成方法及びその利用 |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| EP3157947A1 (en) * | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
| RU2017101436A (ru) | 2014-06-24 | 2018-07-24 | Ново Нордиск А/С | Mic-1 слитные белки и их применение |
| AU2015296640B2 (en) | 2014-07-30 | 2020-05-21 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| EP3701969A1 (en) | 2014-10-31 | 2020-09-02 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| JP6946304B2 (ja) | 2015-12-22 | 2021-10-06 | ノバルティス アーゲー | 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法 |
| MY194669A (en) | 2016-03-31 | 2022-12-12 | Ngm Biopharmaceuticals Inc | Binding Proteins and Methods of use Thereof |
| US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| KR102433503B1 (ko) | 2016-05-24 | 2022-08-18 | 노보 노르디스크 에이/에스 | Mic-1 화합물 및 이것의 사용 |
| TWI710377B (zh) | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Ｍｉｃ－１化合物及其用途 |
| KR102010652B1 (ko) * | 2017-08-21 | 2019-08-13 | 서울대학교병원 | 간질환 예측 또는 진단용 조성물 및 이를 이용한 간질환 예측 또는 진단 방법 |
| CN111163795A (zh) | 2017-09-10 | 2020-05-15 | 诺沃挪第克公司 | 用于治疗肥胖症的mic-1和glp-1 |
| TWI724392B (zh) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| CR20200510A (es) | 2018-04-09 | 2020-11-26 | Amgen Inc | Protreínas de fusión del factor de diferenciación de crecimiento 15 |
| US20200017600A1 (en) * | 2018-07-13 | 2020-01-16 | Genmab A/S | Variants of cd38 antibody and uses thereof |
| EA202191105A1 (ru) * | 2018-10-22 | 2021-08-03 | Янссен Фармацевтика Нв | Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение |
| PE20220500A1 (es) * | 2019-04-23 | 2022-04-07 | Lg Chemical Ltd | POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15 |
| JP7500619B2 (ja) | 2019-05-30 | 2024-06-17 | アムジエン・インコーポレーテツド | 抗体の二量体化を促進するためのヒンジ領域の操作 |
| MA56110A (fr) | 2019-06-07 | 2022-04-13 | Amgen Inc | Constructions de liaison bispécifiques à lieurs clivables de manière sélective |
| EP4041281B1 (en) | 2019-10-04 | 2025-11-26 | Amgen Inc. | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
| KR20220150270A (ko) | 2019-10-07 | 2022-11-10 | 칼리오페, 인크. | Gpr119 효능제 |
| CA3161302A1 (en) * | 2019-11-26 | 2021-06-03 | Yuhan Corporation | Long-acting gdf15 fusion protein and pharmaceutical composition comprising same |
| CA3159979A1 (en) * | 2019-12-11 | 2021-06-17 | Yeonchul Kim | Fusion polypeptide comprising gdf15 and polypeptide region capable of o-glycosylation |
| PH12022551598A1 (en) | 2019-12-23 | 2023-11-20 | Denali Therapeutics Inc | Progranulin variants |
| CN115379850A (zh) * | 2019-12-24 | 2022-11-22 | 裘美娜治疗公司 | 再生性多肽及其用途 |
| EP4085077A4 (en) | 2019-12-31 | 2024-01-17 | Beijing QL Biopharmaceutical Co., Ltd. | Fusion proteins of glp-1 and gdf15 and conjugates thereof |
| WO2021168413A1 (en) * | 2020-02-20 | 2021-08-26 | Neutrolis, Inc. | Basic domain-deleted dnase1-like 3 and uses thereof |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| WO2021236617A1 (en) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Ampk activators |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
| EP4237438A4 (en) | 2020-10-27 | 2024-11-27 | Beijing QL Biopharmaceutical Co., Ltd. | GDF15 FUSION PROTEINS AND THEIR USE |
| WO2022219495A1 (en) | 2021-04-12 | 2022-10-20 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| US20240391971A1 (en) * | 2021-08-24 | 2024-11-28 | Sunshine Lake Pharma Co., Ltd. | Gdf15 fusion proteins and uses thereof |
| CA3233084A1 (en) * | 2021-09-24 | 2023-03-30 | Bionsystems Inc | Fusion protein dimer comprising pd-1 and il-21, and use thereof |
| EP4476212A1 (en) | 2022-02-10 | 2024-12-18 | Novartis AG | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
| CN114835810B (zh) * | 2022-03-31 | 2024-01-05 | 浙江特瑞思药业股份有限公司 | 一种抗pd-1纳米抗体及其应用 |
| WO2025024658A1 (en) * | 2023-07-27 | 2025-01-30 | Binacea Pharma, Inc. | Mutant il-2 fusions with immune cell specific binding proteins and methods of use thereof |
| US20250163119A1 (en) | 2023-11-17 | 2025-05-22 | Eli Lilly And Company | Compounds for the treatment of diabetes or obesity |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| WO1999006445A1 (en) * | 1997-07-31 | 1999-02-11 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-15 |
| HUP0105090A2 (hu) * | 1999-01-07 | 2002-04-29 | Lexigen Pharmaceuticals Corporation | Kóros elhízás elleni fehérjék expressziója és exportja Fc fúziós fehérje formájában |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| US20030103978A1 (en) | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
| IL155812A0 (en) | 2000-12-07 | 2003-12-23 | Lilly Co Eli | Glp-1 fusion proteins |
| TW200526779A (en) * | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| AU2002250293B2 (en) | 2001-03-09 | 2007-10-11 | Arnason, Barry G. Mr | Polymeric immunoglobulin fusion proteins that target low-affinity FCGammaReceptors |
| JP4422949B2 (ja) | 2001-06-26 | 2010-03-03 | 武田薬品工業株式会社 | ＴＧＦ−βスーパーファミリー産生・分泌促進剤 |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| US7332474B2 (en) | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
| US7662925B2 (en) * | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US7101852B2 (en) | 2003-05-30 | 2006-09-05 | The Board Of Regents Of The University Of Texas System | Composition and method for treatment and prevention of restenosis |
| RU2322261C2 (ru) * | 2003-06-02 | 2008-04-20 | Уайт | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| ES2383300T3 (es) * | 2003-11-13 | 2012-06-20 | Hanmi Holdings Co., Ltd | Fragmento Fc de IgG para un vehículo de fármacos y procedimiento para su preparación |
| EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| EP2441466B1 (en) | 2004-04-13 | 2014-07-23 | St Vincent's Hospital Sydney Limited | MIC-1 inhibiting agent |
| WO2005113585A2 (en) * | 2004-05-20 | 2005-12-01 | Acceleron Pharma Inc. | Modified tgf-beta superfamily polypeptides |
| US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| AU2005272646A1 (en) * | 2004-08-12 | 2006-02-23 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors |
| WO2007041635A2 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| CN101356189A (zh) * | 2005-11-10 | 2009-01-28 | 受体生物公司 | 肝细胞生长因子内含子融合蛋白 |
| CN1974601A (zh) * | 2005-11-28 | 2007-06-06 | 上海新生源医药研究有限公司 | 一种新型Fc融合蛋白及其生产方法 |
| WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| US20100278843A1 (en) | 2007-08-16 | 2010-11-04 | St. Vincent's Hospital Sydney Limited | Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| WO2009141357A1 (en) | 2008-05-20 | 2009-11-26 | Roche Diagnostics Gmbh | Gdf-15 as biomarker in type 1 diabetes |
| EP2318529B1 (en) | 2008-08-04 | 2017-10-18 | Five Prime Therapeutics, Inc. | Fgfr extracellular domain acidic region muteins |
| JP5444363B2 (ja) * | 2008-10-31 | 2014-03-19 | セントビンセンツ ホスピタル シドニー リミテッド | 慢性腎疾患における予後判定の方法 |
| MX340971B (es) | 2009-11-23 | 2016-08-02 | Amgen Inc * | Fragmento cristalizable (fc) de anticuerpo monomerico. |
| WO2011064758A2 (en) * | 2009-11-30 | 2011-06-03 | Pfizer Limited | Fusion protein |
| EP2679234A3 (en) * | 2009-12-02 | 2014-04-23 | Amgen Inc. | Binding proteins that bind to human FGFR1C, human beta-klotho and both human FGFR1C and human beta-klotho |
| WO2011091078A2 (en) | 2010-01-19 | 2011-07-28 | Xencor, Inc. | Antibody fc variants with enhanced complement activity |
| CA2804351A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
| JP2013531030A (ja) | 2010-07-12 | 2013-08-01 | ファイザー・リミテッド | 電位開口型ナトリウムチャネルの阻害剤としてのｎ−スルホニルベンズアミド |
| JP2013532185A (ja) | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 化合物 |
| CN108387744A (zh) | 2010-08-26 | 2018-08-10 | 弗·哈夫曼-拉罗切有限公司 | 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途 |
| EP2439535A1 (en) | 2010-10-07 | 2012-04-11 | F. Hoffmann-La Roche AG | Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus |
| ES2758994T3 (es) * | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| EP2686345B1 (en) | 2011-03-16 | 2018-04-25 | Amgen Inc. | Fc variants |
| EP2694092B1 (en) | 2011-04-08 | 2017-01-04 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| EP3415528B1 (en) * | 2011-04-13 | 2021-05-26 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| RS60499B1 (sr) * | 2011-12-20 | 2020-08-31 | Medimmune Llc | Modifikovani polipeptidi za bispecifične skelete antitela |
| EP3683228A3 (en) | 2012-01-26 | 2020-07-29 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) polypeptides |
| CA2862516C (en) | 2012-03-27 | 2023-02-14 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| US9248181B2 (en) * | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
| ES2791183T3 (es) | 2012-12-21 | 2020-11-03 | Aveo Pharmaceuticals Inc | Anticuerpos anti-GDF15 |
| KR101993714B1 (ko) * | 2013-01-30 | 2019-06-28 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사 장애를 치료하는데 이용하기 위한 조성물과 방법 |
| US9862752B2 (en) | 2013-07-31 | 2018-01-09 | Amgen Inc. | Growth differentiation factor 15 (GDF-15) constructs |
| EP3157947A1 (en) * | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| SG11201609706VA (en) | 2014-06-23 | 2017-01-27 | Novartis Ag | Site specific protein modifications |
| RU2017101436A (ru) | 2014-06-24 | 2018-07-24 | Ново Нордиск А/С | Mic-1 слитные белки и их применение |
| JP6946304B2 (ja) | 2015-12-22 | 2021-10-06 | ノバルティス アーゲー | 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法 |
| US10336812B2 (en) | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| KR102433503B1 (ko) | 2016-05-24 | 2022-08-18 | 노보 노르디스크 에이/에스 | Mic-1 화합물 및 이것의 사용 |
| TWI724392B (zh) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
-
2014
- 2014-07-31 US US14/908,459 patent/US9862752B2/en active Active
- 2014-07-31 CN CN202110685579.XA patent/CN113527512A/zh active Pending
- 2014-07-31 AP AP2016009011A patent/AP2016009011A0/xx unknown
- 2014-07-31 AR ARP140102882A patent/AR097181A1/es active IP Right Grant
- 2014-07-31 NZ NZ754961A patent/NZ754961A/en unknown
- 2014-07-31 UA UAA201601817A patent/UA116665C2/uk unknown
- 2014-07-31 KR KR1020237043685A patent/KR20240000642A/ko not_active Ceased
- 2014-07-31 MA MA38873A patent/MA38873B1/fr unknown
- 2014-07-31 WO PCT/US2014/049254 patent/WO2015017710A1/en not_active Ceased
- 2014-07-31 AU AU2014296107A patent/AU2014296107B2/en active Active
- 2014-07-31 MX MX2016001164A patent/MX369152B/es active IP Right Grant
- 2014-07-31 EP EP20189041.5A patent/EP3763734A1/en active Pending
- 2014-07-31 EA EA201690297A patent/EA037355B1/ru not_active IP Right Cessation
- 2014-07-31 NZ NZ717030A patent/NZ717030A/en unknown
- 2014-07-31 SG SG11201600713RA patent/SG11201600713RA/en unknown
- 2014-07-31 PE PE2016000103A patent/PE20160189A1/es unknown
- 2014-07-31 KR KR1020167005421A patent/KR102376451B1/ko active Active
- 2014-07-31 DK DK14752711.3T patent/DK3027642T3/da active
- 2014-07-31 EP EP14752711.3A patent/EP3027642B1/en active Active
- 2014-07-31 KR KR1020227008673A patent/KR102616674B1/ko active Active
- 2014-07-31 UY UY0001035686A patent/UY35686A/es active IP Right Grant
- 2014-07-31 PT PT147527113T patent/PT3027642T/pt unknown
- 2014-07-31 CA CA2918624A patent/CA2918624C/en active Active
- 2014-07-31 HU HUE14752711A patent/HUE050630T2/hu unknown
- 2014-07-31 TN TN2016000035A patent/TN2016000035A1/en unknown
- 2014-07-31 SI SI201431664T patent/SI3027642T1/sl unknown
- 2014-07-31 TW TW103126283A patent/TWI648401B/zh active
- 2014-07-31 ES ES14752711T patent/ES2828670T3/es active Active
- 2014-07-31 PL PL14752711T patent/PL3027642T3/pl unknown
- 2014-07-31 BR BR112016002213A patent/BR112016002213A2/pt not_active Application Discontinuation
- 2014-07-31 JP JP2016531912A patent/JP6509852B2/ja active Active
- 2014-07-31 CN CN201480043522.8A patent/CN105980400B/zh active Active
- 2014-07-31 EA EA202092386A patent/EA202092386A1/ru unknown
- 2014-07-31 MX MX2019012848A patent/MX387211B/es unknown
- 2014-07-31 LT LTEP14752711.3T patent/LT3027642T/lt unknown
- 2014-08-03 JO JOP/2014/0240A patent/JO3566B1/ar active
-
2016
- 2016-01-24 IL IL243749A patent/IL243749B/en active IP Right Grant
- 2016-01-25 ZA ZA2016/00523A patent/ZA201600523B/en unknown
- 2016-01-29 PH PH12016500208A patent/PH12016500208B1/en unknown
- 2016-01-29 CL CL2016000249A patent/CL2016000249A1/es unknown
- 2016-02-29 CR CR20160097A patent/CR20160097A/es unknown
-
2017
- 2017-11-29 US US15/826,442 patent/US10894814B2/en active Active
-
2019
- 2019-04-02 JP JP2019070364A patent/JP6877478B2/ja active Active
-
2020
- 2020-10-09 CY CY20201100954T patent/CY1123836T1/el unknown
- 2020-11-11 US US17/094,968 patent/US20210079051A1/en not_active Abandoned
-
2021
- 2021-04-26 JP JP2021073836A patent/JP2021113219A/ja active Pending
-
2023
- 2023-06-16 JP JP2023099006A patent/JP2023116723A/ja active Pending
-
2024
- 2024-04-18 US US18/639,202 patent/US20240368236A1/en active Pending
- 2024-11-07 JP JP2024195157A patent/JP2025024032A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL243749A0 (en) | Growth differentiation factor templates 15 | |
| IL233725A0 (en) | Growth and differentiation factor 15 (gdf-15) polypeptides | |
| IL235832A0 (en) | Fibroblastic growth factor 21 proteins | |
| GB2530923B (en) | Smart shaker room | |
| ZA201603218B (en) | Afucosylated anti-fgfr2iiib antibodies | |
| GB201302597D0 (en) | Novel Synthetic Proteins | |
| DK3035958T3 (en) | Svine-circovirus type 2 (pcv2) subunit-vaccine | |
| KR101391404B9 (ko) | 골신장기 | |
| SI3016977T1 (sl) | Humana protitelesa proti IL-32 | |
| ZA201508035B (en) | Epidermal growth factor receptor antibody | |
| PL3511466T3 (pl) | Zwoje w kształcie symbolu nieskończoności | |
| GB201312513D0 (en) | 2 4 1 Technology | |
| GB2515170B (en) | Horticultural preparation or formulation | |
| GB201304642D0 (en) | 02 Planter | |
| GB201308820D0 (en) | Part 3 under | |
| GB201322568D0 (en) | Taggstar 1 | |
| AU350588S (en) | Joiner (1) | |
| AU350589S (en) | Joiner (2) | |
| GB201310407D0 (en) | Plantladders 3 | |
| GB201310285D0 (en) | Twist-Away 270 |